RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Immunoprecise Antibodies Stock

Immunoprecise Antibodies Net Income 2024

Immunoprecise Antibodies Net Income

-13.1 M CAD

Ticker

IPA

ISIN

CA45257F2008

WKN

A2QJEC

In 2024, Immunoprecise Antibodies's profit amounted to -13.1 M CAD, a -50.69% increase from the -26.56 M CAD profit recorded in the previous year.

The Immunoprecise Antibodies Net Income history

YEARNET INCOME (undefined CAD)
2030e26.6
2029e18.2
2028e9.53
2027e0.83
2026e-5.24
2025e-9.51
2024e-13.1
2023-26.56
2022-16.71
2021-7.34
2020-4.95
2019-7.62
2018-5.17
2017-5.38
2015-0.03
2014-0.06
20130.07
2012-0.1
2011-0.28
2010-5.29
2009-0.99
2008-0.47
2007-0.76
2006-0.4
20050.17
2004-0.19
2003-0.57

Immunoprecise Antibodies Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Immunoprecise Antibodies, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Immunoprecise Antibodies from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Immunoprecise Antibodies’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Immunoprecise Antibodies. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Immunoprecise Antibodies’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Immunoprecise Antibodies’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Immunoprecise Antibodies’s growth potential.

Immunoprecise Antibodies Revenue, EBIT and net profit per share

DateImmunoprecise Antibodies RevenueImmunoprecise Antibodies EBITImmunoprecise Antibodies Net Income
2030e83.29 M undefined0 undefined26.6 M undefined
2029e68.05 M undefined18.95 M undefined18.2 M undefined
2028e55.62 M undefined9.84 M undefined9.53 M undefined
2027e44.9 M undefined2.08 M undefined827,190 undefined
2026e36.75 M undefined-4.32 M undefined-5.24 M undefined
2025e29.35 M undefined-9.24 M undefined-9.51 M undefined
2024e24.84 M undefined-13.98 M undefined-13.1 M undefined
202320.67 M undefined-28.55 M undefined-26.56 M undefined
202219.36 M undefined-16.24 M undefined-16.71 M undefined
202117.91 M undefined-6.92 M undefined-7.34 M undefined
202014.06 M undefined-4.1 M undefined-4.95 M undefined
201910.93 M undefined-6.23 M undefined-7.62 M undefined
20185.44 M undefined-4.78 M undefined-5.17 M undefined
20172.63 M undefined-1.34 M undefined-5.38 M undefined
20150 undefined-7,000 undefined-32,000 undefined
20140 undefined-37,000 undefined-62,000 undefined
20130 undefined-98,000 undefined69,000 undefined
20120 undefined-82,000 undefined-96,000 undefined
20110 undefined-208,000 undefined-276,000 undefined
20100 undefined-96,000 undefined-5.29 M undefined
20090 undefined-269,000 undefined-991,000 undefined
20080 undefined-402,000 undefined-472,000 undefined
20070 undefined-616,000 undefined-757,000 undefined
20060 undefined-237,000 undefined-404,000 undefined
20050 undefined-206,000 undefined166,000 undefined
20040 undefined-200,000 undefined-186,000 undefined
20030 undefined-309,000 undefined-565,000 undefined

Immunoprecise Antibodies stock margins

The Immunoprecise Antibodies margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Immunoprecise Antibodies. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Immunoprecise Antibodies.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Immunoprecise Antibodies's sales revenue. A higher gross margin percentage indicates that the Immunoprecise Antibodies retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Immunoprecise Antibodies's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Immunoprecise Antibodies's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Immunoprecise Antibodies's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Immunoprecise Antibodies. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Immunoprecise Antibodies's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Immunoprecise Antibodies Margin History

Immunoprecise Antibodies Gross marginImmunoprecise Antibodies Profit marginImmunoprecise Antibodies EBIT marginImmunoprecise Antibodies Profit margin
2030e55.95 %0 %31.93 %
2029e55.95 %27.86 %26.74 %
2028e55.95 %17.69 %17.14 %
2027e55.95 %4.62 %1.84 %
2026e55.95 %-11.74 %-14.26 %
2025e55.95 %-31.48 %-32.41 %
2024e55.95 %-56.3 %-52.74 %
202355.95 %-138.16 %-128.53 %
202256.72 %-83.88 %-86.29 %
202164.41 %-38.63 %-40.98 %
202057.15 %-29.13 %-35.19 %
201948.46 %-56.99 %-69.71 %
201845.05 %-87.8 %-95.04 %
201755.95 %-51.01 %-204.64 %
201555.95 %0 %0 %
201455.95 %0 %0 %
201355.95 %0 %0 %
201255.95 %0 %0 %
201155.95 %0 %0 %
201055.95 %0 %0 %
200955.95 %0 %0 %
200855.95 %0 %0 %
200755.95 %0 %0 %
200655.95 %0 %0 %
200555.95 %0 %0 %
200455.95 %0 %0 %
200355.95 %0 %0 %

Immunoprecise Antibodies Aktienanalyse

What does Immunoprecise Antibodies do?

Immunoprecise Antibodies Ltd is a leading company in the development of antibodies and antibody-based solutions for the pharmaceutical and biotech industry. The company was founded in 2015 as a spin-off from the University of Victoria in Canada and has since experienced rapid growth, expanding into other countries such as the USA, Europe, and Asia. The company's unique business model is based on three pillars: providing innovative research services tailored to the needs of the pharmaceutical and biotech industry, offering a broad portfolio of antibody products for research and diagnostics, and developing a pipeline of new therapeutics currently undergoing clinical trials. The core business of Immunoprecise Antibodies Ltd is the manufacturing of antibodies and antibody-based solutions for research and diagnostics. The company offers a range of innovative services, including antibody engineering, production and purification, and characterization. The research services are provided by an experienced team of scientists and experts in the field of antibody research who work closely with customers to meet their specific needs. In addition, the company has a wide range of antibody products available for various applications in research and diagnostics, including protein quantification, immunohistochemistry, cancer antigen detection, influenza diagnostics, and many others. Immunoprecise Antibodies Ltd has also developed a pipeline of new therapeutics, including antibodies against cancer, inflammation, and infectious diseases, which are currently undergoing clinical trials. The company collaborates closely with leading pharmaceutical and biotech companies to advance the latest developments in this field. To enable better focus and specialization, Immunoprecise Antibodies Ltd is divided into six divisions: humanization/antibody engineering, antibody production, antibody characterization, immunohistochemistry, therapeutics development, and process development. These divisions are strategically designed to cover the needs of customers and facilitate an effective supply chain for antibody production and development. Immunoprecise Antibodies Ltd is a young and dynamic company with a strong focus on innovation and customer satisfaction. It has earned an excellent reputation in the industry and is regarded as a valuable partner for antibody research and development by leading pharmaceutical and biotech companies. The company's goal is to remain a key player in the field of antibody research and continue developing innovative solutions for the pharmaceutical and biotech industry. Immunoprecise Antibodies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Immunoprecise Antibodies's Profit Margins

The profit margins of Immunoprecise Antibodies represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Immunoprecise Antibodies's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Immunoprecise Antibodies's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Immunoprecise Antibodies's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Immunoprecise Antibodies’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Immunoprecise Antibodies stock

How much profit has Immunoprecise Antibodies made this year?

Immunoprecise Antibodies has made -13.1 M CAD this year.

How has the profit developed compared to last year?

The profit has increased by -50.69% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Immunoprecise Antibodies publish its earnings?

Immunoprecise Antibodies publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Immunoprecise Antibodies?

The profits of Immunoprecise Antibodies are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Immunoprecise Antibodies?

You can learn more about the earnings of Immunoprecise Antibodies by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Immunoprecise Antibodies pay?

Over the past 12 months, Immunoprecise Antibodies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunoprecise Antibodies is expected to pay a dividend of 0 CAD.

What is the dividend yield of Immunoprecise Antibodies?

The current dividend yield of Immunoprecise Antibodies is .

When does Immunoprecise Antibodies pay dividends?

Immunoprecise Antibodies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Immunoprecise Antibodies?

Immunoprecise Antibodies paid dividends every year for the past 0 years.

What is the dividend of Immunoprecise Antibodies?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Immunoprecise Antibodies located?

Immunoprecise Antibodies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immunoprecise Antibodies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immunoprecise Antibodies from 9/26/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.

When did Immunoprecise Antibodies pay the last dividend?

The last dividend was paid out on 9/26/2024.

What was the dividend of Immunoprecise Antibodies in the year 2023?

In the year 2023, Immunoprecise Antibodies distributed 0 CAD as dividends.

In which currency does Immunoprecise Antibodies pay out the dividend?

The dividends of Immunoprecise Antibodies are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Immunoprecise Antibodies

Our stock analysis for Immunoprecise Antibodies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunoprecise Antibodies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.